Evidence map›Paper›PMID 37698830›Full record

ArticlePharmacological reports : PR2023

HDAC3 inhibition protects against peripheral and central alterations in an animal model of obesity.

Franciéle Romero Machado, Silvana Peterini Boeira, Vandreza Cardoso Bortolotto, Stífani Machado Araujo, Márcia Rósula Poetini, Cristini Escobar Viana, Marina Prigol, Leandro Cattelan Souza, Marcelo Gomes de Gomes

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmacological reports : PR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Franciéle Romero MachadoLaboratory of Pharmacological and Toxicological Evaluations Applied to Bioactive Molecules, LaftamBio Pampa, Federal University of Pampa, Campus Itaqui, Itaqui, RS, 97650-000, Brazil.
Silvana Peterini BoeiraLaboratory of Pharmacological and Toxicological Evaluations Applied to Bioactive Molecules, LaftamBio Pampa, Federal University of Pampa, Campus Itaqui, Itaqui, RS, 97650-000, Brazil.
Vandreza Cardoso BortolottoLaboratory of Pharmacological and Toxicological Evaluations Applied to Bioactive Molecules, LaftamBio Pampa, Federal University of Pampa, Campus Itaqui, Itaqui, RS, 97650-000, Brazil.
Stífani Machado AraujoLaboratory of Pharmacological and Toxicological Evaluations Applied to Bioactive Molecules, LaftamBio Pampa, Federal University of Pampa, Campus Itaqui, Itaqui, RS, 97650-000, Brazil.
Márcia Rósula PoetiniLaboratory of Pharmacological and Toxicological Evaluations Applied to Bioactive Molecules, LaftamBio Pampa, Federal University of Pampa, Campus Itaqui, Itaqui, RS, 97650-000, Brazil.
Cristini Escobar VianaLaboratory of Pharmacological and Toxicological Evaluations Applied to Bioactive Molecules, LaftamBio Pampa, Federal University of Pampa, Campus Itaqui, Itaqui, RS, 97650-000, Brazil.
Marina PrigolLaboratory of Pharmacological and Toxicological Evaluations Applied to Bioactive Molecules, LaftamBio Pampa, Federal University of Pampa, Campus Itaqui, Itaqui, RS, 97650-000, Brazil.
Leandro Cattelan SouzaLaboratory of Pharmacological and Toxicological Evaluations Applied to Bioactive Molecules, LaftamBio Pampa, Federal University of Pampa, Campus Itaqui, Itaqui, RS, 97650-000, Brazil.
Marcelo Gomes de GomesLaboratory of Pharmacological and Toxicological Evaluations Applied to Bioactive Molecules, LaftamBio Pampa, Federal University of Pampa, Campus Itaqui, Itaqui, RS, 97650-000, Brazil. marcelogomesdegomes@hotmail.com.ORCID http://orcid.org/0000-0001-9017-5979
Universidade Federal do Pampa · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundObesity is a multifactorial disease with epigenetic manifestations that increases the prevalence of associated comorbidities such as metabolic syndrome, cardiovascular dysfunction, and major depression disorder. Given the aforementioned, a search for new pharmacological alternatives for the treatment of this disease is necessary. The current study aimed to evaluate the effects of histone deacetylase-3 (HDAC3) inhibition caused by RGFP966 (a benzamide-type HDAC inhibitor selective for HDAC3) administration, in an animal model of obesity induced by high-fat diet (HFD).

methodsAdult male mice C57BJ/6 were fed with a normal pellet diet (NPD) or HFD for 120 days. The HDAC3 inhibitor (RGFP966; 10 mg/kg; sc) was administered on the 91st to 120th day of the experiment (per 30 days). After the last inhibitor administration, animals were euthanized, blood was collected, and the hippocampus was removed for biochemical determinations.

resultsIn an overall manner, the administration of RGFP966 protected against changes in body weight gain, glucose, insulin, lipid profile, adipokines, and increase of hippocampal proinflammatory cytokines levels caused by HFD.

conclusionTherefore, HDAC3 inhibition can represent a promising pharmacological target for the treatment of obesity.

Indexed as

AcrylamidesHistone Deacetylase InhibitorsHistone DeacetylasesObesityPhenylenediaminesAdipokinesAnimalsBlood GlucoseCytokinesDiet, High-FatDisease Models, AnimalHippocampusInsulinMaleMiceMice, Inbred C57BLAcrylamidesAdipokinesBlood GlucoseCytokinesHistone Deacetylase InhibitorsHistone DeacetylasesInsulinPhenylenediaminesRGFP966EpigeneticMetabolismNeuroinflammationNutritionObesity

Identifiers

PMID37698830
OpenAlexW4386624118

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.